Home Compounds Longevity & Mitochondrial Glutathione
Longevity & Mitochondrial Research Moderate Evidence

Glutathione

Master antioxidant tripeptide (GSH). Studied for detoxification support, oxidative stress reduction, immune function, and skin health applications.

antioxidantdetoximmuneskinoxidative stress
Half-life
IV form bioavailable acutely; oral bioavailability debated
SKUs
1
Evidence
Moderate Evidence

Glutathione is a tripeptide made from three amino acids — glutamate, cysteine, and glycine — and is the most abundant antioxidant produced by cells. It plays a central role in protecting cells from oxidative damage, supporting immune function, and assisting with detoxification in the liver. Research has studied both oral and IV supplementation for oxidative stress conditions, liver health, skin lightening, and immune support.

Liver Health Research
Glutathione has been studied in liver conditions including non-alcoholic fatty liver disease and alcoholic liver disease. IV glutathione studies have shown reductions in liver enzyme levels and improvements in oxidative stress markers. Oral glutathione has more variable bioavailability but some studies show liver protection signals.
Oxidative Stress and Aging
Glutathione levels decline with age and with many chronic diseases. Research has examined whether supplementation can restore cellular antioxidant capacity. Studies show IV glutathione reliably raises blood glutathione levels, and some research links this to improvements in immune function and inflammatory markers.
Skin Lightening Research
IV and oral glutathione have been studied for their effects on melanin production. Research suggests glutathione may redirect melanin synthesis toward lighter pigment forms. This application is particularly studied in East and Southeast Asian research contexts.
Neurological Research
Glutathione depletion has been observed in Parkinson's disease brain tissue. Small studies of IV glutathione in Parkinson's patients have shown some symptom improvements, though larger trials have not confirmed this. The neuroprotective interest relates to the high oxidative stress environment in affected brain regions.
  • IV glutathione reliably raises blood and tissue glutathione levels.
  • Liver enzyme reductions observed in NAFLD and liver disease studies.
  • Some evidence for immune function improvements and reductions in oxidative stress markers.
  • Mixed evidence for oral forms due to inconsistent bioavailability.
  • Small Parkinson's studies showed symptom improvements but have not been confirmed in larger trials.

Oral glutathione bioavailability has historically been considered low, as the tripeptide is broken down in digestion. Newer liposomal and s-acetyl forms may improve this, but quality of evidence for oral forms is limited. Most research showing meaningful effects uses IV administration. Glutathione has no FDA-approved use as a drug, though IV formulations are used clinically in some contexts. Long-term effects of regular supplementation are not established.

Every cell produces glutathione internally from three amino acids. It works as the body's primary internal antioxidant, neutralizing reactive oxygen species that are produced constantly as byproducts of normal metabolism — and that ramp up significantly during illness, injury, stress, and aging. It also helps the liver tag and process toxic compounds for elimination from the body. When cellular glutathione is depleted, cells become more vulnerable to oxidative damage. Supplementing glutathione — particularly through IV administration — aims to replenish these levels in contexts where the body's own production has fallen behind demand.

Glutathione has a generally favorable safety record in research and clinical use. IV administration can rarely cause allergic reactions. At standard supplementation doses, no serious adverse effects are well-documented. It is not FDA-approved as a drug. Oral supplement quality varies considerably, and many products may not deliver meaningful amounts of intact glutathione. Nebulized glutathione has been reported to cause bronchospasm in some people with asthma.

Moderate Evidence

This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.

Published Research Ranges
600–1200mg IV in published studies
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Glutathione and Its Role in Cellular Functions
Free Radical Biology and Medicine • 1999  • DOI: 10.1016/S0891-5849(99)00003-2
View Source
Oral Glutathione Supplementation and Skin Lightening: Randomized Controlled Trial
Clinical, Cosmetic and Investigational Dermatology • 2014  • DOI: 10.2147/CCID.S58142
View Source
Intravenous Glutathione in Non-Alcoholic Fatty Liver Disease: Pilot Randomized Trial
Journal of Gastroenterology • 2017  • DOI: 10.1007/s00535-016-1301-5
View Source
Bioavailability of Oral Glutathione in Healthy Adults
European Journal of Nutrition • 2015  • DOI: 10.1007/s00394-014-0702-4
View Source
Antioxidants prevent health-promoting effects of physical exercise in humans
 • 2009  • DOI: 10.1073/pnas.0903485106
View Source
Macrophages in immunoregulation and therapeutics
 • 2023  • DOI: 10.1038/s41392-023-01452-1
View Source
The blood-brain barrier: structure, regulation, and drug delivery
 • 2023  • DOI: 10.1038/s41392-023-01481-w
View Source
Connecting copper and cancer: from transition metal signalling to metalloplasia
 • 2022  • DOI: 10.1038/s41568-021-00417-2
View Source
Targeting oxidative stress in disease: promise and limitations of antioxidant therapy
 • 2021  • DOI: 10.1038/s41573-021-00233-1
View Source
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
 • 2021  • DOI: 10.1007/s13238-020-00789-5
View Source
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics
 • 2021  • DOI: 10.1038/s41575-021-00440-6
View Source
Reprogramming of fatty acid metabolism in cancer
 • 2020  • DOI: 10.1038/s41416-019-0650-z
View Source
Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies
 • 2020  • DOI: 10.3390/ijms21114012
View Source
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
 • 2020  • DOI: 10.1038/s41392-020-00311-7
View Source
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
 • 2019  • DOI: 10.1039/c8cs00618k
View Source
Nanozyme: new horizons for responsive biomedical applications
 • 2019  • DOI: 10.1039/c8cs00718g
View Source
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
 • 2019  • DOI: 10.1021/acs.chemrev.8b00363
View Source
Endoplasmic reticulum stress signalling - from basic mechanisms to clinical applications
 • 2019  • DOI: 10.1111/febs.14608
View Source
Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy
 • 2019  • DOI: 10.1002/anie.201804882
View Source
Oxidative stress, aging, and diseases
 • 2018  • DOI: 10.2147/cia.s158513
View Source
Mechanisms of Insulin Action and Insulin Resistance
 • 2018  • DOI: 10.1152/physrev.00063.2017
View Source
Gut microbiota functions: metabolism of nutrients and other food components
 • 2018  • DOI: 10.1007/s00394-017-1445-8
View Source
Chemical Biology of H2S Signaling through Persulfidation
 • 2018  • DOI: 10.1021/acs.chemrev.7b00205
View Source
Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease
 • 2017  • DOI: 10.1016/j.cell.2017.09.021
View Source
One-Carbon Metabolism in Health and Disease
 • 2017  • DOI: 10.1016/j.cmet.2016.08.009
View Source
Curcumin: A Review of Its Effects on Human Health
 • 2017  • DOI: 10.3390/foods6100092
View Source
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
 • 2017  • DOI: 10.1016/j.cmet.2016.12.022
View Source
Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease
 • 2017  • DOI: 10.3233/jad-161088
View Source
Effects of Probiotics, Prebiotics, and Synbiotics on Human Health
 • 2017  • DOI: 10.3390/nu9091021
View Source
Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits
 • 2017  • DOI: 10.1080/16546628.2017.1361779
View Source
Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review
 • 2019  • DOI: 10.2174/1570159x16666180911123341
View Source
Polyphenols in Parkinson's Disease: A Systematic Review of In Vivo Studies
 • 2018  • DOI: 10.3390/nu10050642
View Source
Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis
 • 2024  • DOI: 10.3390/antiox13040393
View Source
Polymeric Nanoparticles for Drug Delivery
 • 2024  • DOI: 10.1021/acs.chemrev.3c00705
View Source
Cold and hot tumors: from molecular mechanisms to targeted therapy
 • 2024  • DOI: 10.1038/s41392-024-01979-x
View Source
Astrocytes in human central nervous system diseases: a frontier for new therapies
 • 2023  • DOI: 10.1038/s41392-023-01628-9
View Source
Smart nanoparticles for cancer therapy
 • 2023  • DOI: 10.1038/s41392-023-01642-x
View Source
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation
 • 2023  • DOI: 10.1186/s12943-023-01865-0
View Source
Therapeutics in the Pipeline Targeting <i>α</i>-Synuclein for Parkinson's Disease
 • 2022  • DOI: 10.1124/pharmrev.120.000133
View Source
Liposomes: structure, composition, types, and clinical applications
 • 2022  • DOI: 10.1016/j.heliyon.2022.e09394
View Source
Design of therapeutic biomaterials to control inflammation
 • 2022  • DOI: 10.1038/s41578-022-00426-z
View Source
The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain
 • 2021  • DOI: 10.3389/fnagi.2021.654931
View Source
Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage
 • 2021  • DOI: 10.1021/acs.molpharmaceut.0c00474
View Source
PGC-1s in the Spotlight with Parkinson's Disease
 • 2021  • DOI: 10.3390/ijms22073487
View Source
The Chemistry of Reactive Oxygen Species (ROS) Revisited: Outlining Their Role in Biological Macromolecules (DNA, Lipids and Proteins) and Induced Pathologies
 • 2021  • DOI: 10.3390/ijms22094642
View Source
Controlled Drug Delivery Systems: Current Status and Future Directions
 • 2021  • DOI: 10.3390/molecules26195905
View Source
Nanomaterials for cancer therapy: current progress and perspectives
 • 2021  • DOI: 10.1186/s13045-021-01096-0
View Source
Nanoparticles for Cancer Therapy: Current Progress and Challenges
 • 2021  • DOI: 10.1186/s11671-021-03628-6
View Source
Role of brain renin angiotensin system in neurodegeneration: An update
 • 2020  • DOI: 10.1016/j.sjbs.2020.01.026
View Source
The Effects of Cadmium Toxicity
 • 2020  • DOI: 10.3390/ijerph17113782
View Source
Anthocyanins: A Comprehensive Review of Their Chemical Properties and Health Effects on Cardiovascular and Neurodegenerative Diseases
 • 2020  • DOI: 10.3390/molecules25173809
View Source
Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications
 • 2020  • DOI: 10.3389/fphar.2020.01021
View Source
Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application
 • 2020  • DOI: 10.3389/fphar.2020.00697
View Source
Emerging therapies in Parkinson disease - repurposed drugs and new approaches
 • 2019  • DOI: 10.1038/s41582-019-0155-7
View Source
Neurotheranostics as personalized medicines
 • 2019  • DOI: 10.1016/j.addr.2018.10.011
View Source
Recent progress in drug delivery
 • 2019  • DOI: 10.1016/j.apsb.2019.08.003
View Source
Current trends and challenges in cancer management and therapy using designer nanomaterials
 • 2019  • DOI: 10.1186/s40580-019-0193-2
View Source
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
 • 2019  • DOI: 10.1038/s41392-019-0068-3
View Source
An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition
 • 2018  • DOI: 10.1007/s00204-017-2133-4
View Source
Current perspective of mitochondrial biology in Parkinson's disease
 • 2018  • DOI: 10.1016/j.neuint.2018.03.001
View Source

60 sources · Platform research library · Not generated by AI

GTT

Combination use is not endorsed - provided for research context only.

Want More Detailed Research?

Ask the AI anything about Glutathione - mechanisms, trial summaries, pharmacokinetics, and comparisons.

Ask AI About Glutathione
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.